FTSE 100 news / Companies and sectors / AstraZeneca / 21 October 2026
AstraZeneca (AZN): news on Wednesday 21 October 2026
+8.7 strongly positive
Coverage was dominated by positive Phase III results for Tezspire in eosinophilic esophagitis, with a 69% remission rate and a 2.7% share rise reported. A new AI clinical trial partnership with Oracle added a further favourable note, alongside steady analyst views.
What drove it
- Tezspire Phase III results
- Oracle AI partnership
- analyst views
The 38 stories
- +10.0 Amgen, AstraZeneca's Tezspire achieves 69% remission in Phase III EoE trial
69% remission in Phase III trial - +10.0 AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
69% remission in esophageal disease trial - +10.0 Amgen/AstraZeneca unveil strong Ph III results for Tezspire in EoE
Strong Phase III Tezspire results - +10.0 AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
Significant remission shown in EoE study - +10.0 Amgen, AstraZeneca report positive trial results for Tezspire in EoE By Investing.com
Positive Phase III Tezspire results - +10.0 Amgen, AstraZeneca report positive trial results for Tezspire in EoE
Positive Tezspire EoE trial results - +10.0 AstraZeneca reports full results from Phase 3 CROSSING trial of Tezspire
Full Phase 3 CROSSING results reported - +10.0 Amgen, AstraZeneca Detail Phase III Data For Tezspire’s Likely Third Indication
Phase III data for likely third Tezspire indication - +10.0 AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case
Shares up 2.7% on Tezspire data - +10.0 Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis
Phase 3 EoE results reported - +10.0 Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Resul
Positive Phase 3 results reported - +10.0 AstraZeneca’s tezepelumab shows positive results for esophagitis By Investing.com
Positive esophagitis results for tezepelumab - +10.0 AstraZeneca, Amgen announce TEZSPIRE showed ‘significant’ improvements
Significant Tezspire improvements announced - +9.7 Amgen, AstraZeneca Say Tezspire Showed Improvement in Eosinophilic Esophagitis in Phase 3 Study
Tezspire improvement shown in Phase 3 - +9.2 Amgen and AstraZeneca report asthma drug trial results By Investing.com
Asthma drug trial results reported - +7.5 ESMO26: HUTCHMED and AstraZeneca share positive outlook on NSCLC
Positive NSCLC outlook with HUTCHMED - +7.0 AstraZeneca Partners With Oracle to Use AI in Clinical Trials as Drugmaker Targets $80bn Revenue
Oracle AI partnership amid $80bn revenue target - +6.7 AstraZeneca partners with Oracle for AI-driven clinical trials
AI-driven clinical trials partnership with Oracle - +6.7 AstraZeneca seeks smarter trials, earlier care in AI tie-up with Oracle
AI tie-up aims at smarter trials - +6.7 AstraZeneca and Oracle launch global AI collaboration to speed up clinical trial recruitment
Global AI collaboration for trial recruitment - +6.7 Oracle and AstraZeneca use AI to speed clinical trial recruitment and care - CHOSUNBIZ
AI partnership with Oracle to speed trial recruitment - +6.3 Oracle & AstraZeneca to link AI research with care
AI research and care partnership with Oracle - +6.3 AstraZeneca and Oracle partner on AI-driven clinical trials and patient care
AI partnership for trials and patient care - +6.3 AstraZeneca Partners with Oracle to Connect AI Capabilities to Healthcare Innovations
Oracle partnership connecting AI capabilities - +6.3 AstraZeneca Collaborates with Oracle on AI-Powered Clinical Trials
Oracle AI clinical trials collaboration - +6.3 AstraZeneca and Oracle to trial AI to find patients for clinical trials
AI trial patient-finding partnership with Oracle - +6.3 Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation - Software - Oracle Corporation
Partnership to advance AI healthcare innovation - +5.8 Oracle announced on the 21st that it has signed an agreement with AstraZeneca to support medical sta..
Oracle agreement supporting medical staff and trials - +5.0 AstraZeneca and Oracle AI Trial Pact: Can the Partnership Reset the Market’s Pricing?
Oracle AI pact and market pricing question - +5.0 Oracle Stocks Rise 2.4% as AstraZeneca Pact Opens an AI Healthcare Test
Oracle pact with AstraZeneca; focus on Oracle's shares - +5.0 Jefferies sees 59% chance AstraZeneca's kidney drug zibotentan succeeds in phase 3 trial by 2027
Jefferies sees decent chance zibotentan succeeds - +5.0 Oracle (ORCL) Expands Its AI Healthcare Push With A New Drugmaker Partnership
Oracle AI push with AstraZeneca partnership - +4.2 AstraZeneca stock: Jefferies keeps GBP 175.00 target pre-market
Jefferies maintains a high price target - +4.2 Oracle unveils AstraZeneca AI clinical-trial agreement: ORCL struggles to rise
Oracle-focused story on AstraZeneca AI agreement - +3.3 Cambridge and AstraZeneca extend programme to support PhD students
Extended PhD support programme with Cambridge - +2.5 AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple?
Oncology catalysts but questions over valuation - +2.5 Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
Roundup mentioning AstraZeneca AI deal - +0.8 AstraZeneca stock: Zacks upgrades AstraZeneca to Hold as results near for AstraZeneca stock
Zacks upgrade only to Hold
AstraZeneca: every day · Pharma and healthcare on 21 October 2026 · FTSE 100 overview for the day